LivaNova (NASDAQ:LIVN) Issues FY 2024 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 3.300-3.400 for the period, compared to the consensus estimate of 3.160. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

LivaNova Stock Down 0.4 %

Shares of LIVN opened at $52.97 on Wednesday. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -88.28 and a beta of 1.00. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.47. The stock’s 50-day moving average price is $50.83 and its 200-day moving average price is $53.16. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.66 by $0.15. The business had revenue of $318.60 million for the quarter, compared to analyst estimates of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. On average, sell-side analysts predict that LivaNova will post 2.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Stifel Nicolaus lifted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Robert W. Baird upgraded LivaNova from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $55.00 to $66.00 in a research note on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price target on the stock. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Needham & Company LLC increased their target price on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, LivaNova has a consensus rating of “Buy” and an average price target of $69.83.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.